17:
67:
antigen (old name: PL). The patient develops antibodies to the HPA-1a antigen leading to platelet destruction. In some cases, HPA-5b has also been implicated. It is unclear why alloantibodies attack the patient's own, as well as any transfused allogeneic random donor platelets. Probable explanation
250:
Schwartz, Joseph; Padmanabhan, Anand; Aqui, Nicole; Balogun, Rasheed A.; Connelly-Smith, Laura; Delaney, Meghan; Dunbar, Nancy M.; Witt, Volker; Wu, Yanyun (June 2016). "Guidelines on the Use of
Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the
62:
PTP is rare, but usually occurs in women who have had multiple pregnancies or in people who have undergone previous transfusions. The precise mechanism leading to PTP is unknown, but it most commonly occurs in individuals whose platelets lack the
295:
54:, a rapid decline in platelet count. PTP usually presents 5–12 days after transfusion, and is a potentially fatal condition in rare cases. Approximately 85% of cases occur in women.
68:
for this is that the recipient's platelets acquire the phenotype of donor's platelet by binding of the soluble antigens from the donor onto the recipient's platelet.
142:
117:
309:
235:
211:
127:
98:
118:
Washington
University School of Medicine; Cooper, Daniel E.; J Krainik, Andrew; J Lubner, Sam; EL Reno, Hilary (2007),
336:
331:
226:
Hillyer, Christopher D.; Hillyer, Krista; Strobl, Frank; Jefferies, Leigh C.; Silberstein, Leslie E. (2001),
204:
Platelets in
Thrombotic and Non-thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics
76:
Symptoms are usually sudden in onset and self-limiting, most often resolving within 2 weeks.
301:
36:
8:
305:
276:
268:
231:
207:
184:
176:
136:
123:
93:
32:
260:
168:
51:
44:
40:
172:
325:
272:
180:
280:
188:
202:
Gresele, Paolo; Page, Clive P.; Fuster, Valentin; Vermylen, Jos (2002),
264:
120:
The
Washington Manual of Medical Therapeutics (Spiral Manual Series)
47:
50:. These alloantibodies destroy the patient's platelets leading to
293:
64:
249:
225:
251:
American
Society for Apheresis: The Seventh Special Issue".
81:
77:
80:
therapy is the primary treatment. Additionally, PTP is an
16:
206:(1st ed.), Cambridge University Press, p. 551,
201:
159:
Savage, William J. (June 2016). "Transfusion
Reactions".
294:Hoffbrand, A. V.; P.A.H. Moss; J.E. Pettit (2006).
323:
230:(1st ed.), Academic Press, p. 328,
161:Hematology/Oncology Clinics of North America
141:: CS1 maint: multiple names: authors list (
122:, Lippincott Williams Wilkins, p. 519,
84:Category III indication for plasmapheresis.
15:
39:that occurs when the body has produced
324:
158:
31:) is a delayed adverse reaction to a
154:
152:
99:Neonatal alloimmune thrombocytopenia
13:
297:Essential Haematology: 5th Edition
14:
348:
149:
228:Handbook of Transfusion Medicine
287:
243:
219:
195:
111:
82:American Society for Apheresis
1:
253:Journal of Clinical Apheresis
104:
43:to the allogeneic transfused
71:
57:
7:
87:
10:
353:
173:10.1016/j.hoc.2016.01.012
25:Post-transfusion purpura
21:
337:Transfusion reactions
19:
332:Transfusion medicine
302:Blackwell Publishing
37:platelet transfusion
22:
311:978-1-4051-3649-5
265:10.1002/jca.21470
237:978-0-12-348775-9
213:978-0-521-80261-1
129:978-0-7817-8125-1
94:Blood transfusion
33:blood transfusion
344:
316:
315:
291:
285:
284:
247:
241:
240:
223:
217:
216:
199:
193:
192:
156:
147:
146:
140:
132:
115:
52:thrombocytopenia
352:
351:
347:
346:
345:
343:
342:
341:
322:
321:
320:
319:
312:
292:
288:
248:
244:
238:
224:
220:
214:
200:
196:
157:
150:
134:
133:
130:
116:
112:
107:
90:
74:
60:
12:
11:
5:
350:
340:
339:
334:
318:
317:
310:
286:
259:(3): 149–162.
242:
236:
218:
212:
194:
167:(3): 619–634.
148:
128:
109:
108:
106:
103:
102:
101:
96:
89:
86:
73:
70:
59:
56:
41:alloantibodies
9:
6:
4:
3:
2:
349:
338:
335:
333:
330:
329:
327:
313:
307:
303:
299:
298:
290:
282:
278:
274:
270:
266:
262:
258:
254:
246:
239:
233:
229:
222:
215:
209:
205:
198:
190:
186:
182:
178:
174:
170:
166:
162:
155:
153:
144:
138:
131:
125:
121:
114:
110:
100:
97:
95:
92:
91:
85:
83:
79:
69:
66:
55:
53:
49:
46:
42:
38:
34:
30:
26:
20:Purpura spots
18:
296:
289:
256:
252:
245:
227:
221:
203:
197:
164:
160:
119:
113:
75:
61:
28:
24:
23:
326:Categories
105:References
45:platelets'
273:1098-1101
181:1558-1977
72:Treatment
58:Mechanism
281:27322218
189:27113000
137:citation
88:See also
48:antigens
308:
279:
271:
234:
210:
187:
179:
126:
65:HPA-1a
306:ISBN
277:PMID
269:ISSN
232:ISBN
208:ISBN
185:PMID
177:ISSN
143:link
124:ISBN
78:IVIG
261:doi
169:doi
35:or
29:PTP
328::
304:.
300:.
275:.
267:.
257:31
255:.
183:.
175:.
165:30
163:.
151:^
139:}}
135:{{
314:.
283:.
263::
191:.
171::
145:)
27:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
